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Abstract
Human fibrocytes are bone marrow-derived mesenchymal progenitor cells that express a variety of markers related
to leukocytes, hematopoietic stem cells and a diverse set of fibroblast phenotypes. Fibrocytes can be recruited
from the circulation to the tissue where they further can differentiate and proliferate into various mesenchymal cell
types depending on the tissue niche. This local tissue niche is important because it modulates the fibrocytes and
coordinates their role in tissue behaviour and repair. However, plasticity of a niche may be co-opted in chronic
airway diseases such as asthma, idiopathic pulmonary fibrosis and obliterative bronchiolitis. This review will
therefore focus on a possible role of fibrocytes in pathological tissue repair processes in those diseases.
Introduction
Tissue repair and remodelling are ongoing processes in
all types of wound healing. In healthy subjects, the pri-
mary role of the extracellular matrix (ECM) is to pro-
vide tissues with specific mechanical properties and to
serve as a structural framework for cell attachment and
migration. An ongoing tissue repair can result in fibro-
sis, which is regarded as an abnormal wound-healing
process. Both resident tissue cells and recruited cells
play significant roles in the pathological tissue repair.
Mesenchymal stem cells and progenitor cells have
recently emerged as being important for maintaining tis-
sue homeostasis. The dynamic relationship between the
stem cells and the niche is very evident during tissue
repair after an injury. Constitutive activation of repair
programs, including accompanying inflammatory
responses, leads to permanent changes in the niche that
can lead to dysregulation of cellular function and stem
cell behaviour. This can ultimately contribute to the dis-
ease progression, and therefore it is necessary to under-
stand the molecular structure and composition of the
niche to understand stem cell behaviour.
Fibrocytes - markers, recruitment, and differentiation
A few years ago tissue-resident fibroblasts were thought
to be the only possible source of fibroblasts. However,
fibrocytes have recently been discovered as one of sev-
eral different precursors of fibroblasts [1]. Epithelial-
mesenchymal transition and endothelial-mesenchymal
transition are also known to be possible sources of
fibroblasts [2,3]. To evaluate the portion that each possi-
ble progenitor contributes to the fibroblast population, a
bleomycin-induced model of lung fibrosis was studied.
In this model, one-third of the fibroblasts were derived
from epithelium and one-fifth from bone marrow. The
proportions derived from endothelial-mesenchymal tran-
sition and from other possible origins were not investi-
gated in this study [4]. Further studies are required to
fully understand the mesenchymal origins of fibroblasts.
Fibrocytes are a distinct sub-population of bone mar-
row-derived fibroblast-like cells that can be found in the
tissue and as circulating cells in peripheral blood. A
combination of specific markers is used to identify fibro-
cytes such as combining haematopoietic markers with
mesenchymal markers. For example, there are molecules
specific for leukocytes (CD45), monocytes (CD11a,
CD11b, CD13), and stem cells (CD34), and also chemo-
kine receptors (CXCR4), major histocompatibility com-
plex (MHC) molecules, and mesenchymal markers
(prolyl 4-hydroxylase, a-smooth muscle actin (a-SMA))
on fibrocytes [1,5-8]. One of the most abundant markers
is CXCR4, which is expressed by 90% of circulating
fibrocytes [9]. The expression of these specific proteins
alters as the fibrocytes are released from the bone mar-
row and recruited to the tissue. Mori et al. (10) isolated
circulating fibrocytes from mice and analysed the cells
regarding their CD13, CD34, CD45, collagen I, and a-
SMA expression for one week in serum-free medium or
in medium supplemented with transforming growth fac-
tor (TGF) -b, a factor involved in wound healing. The
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whereas the expression of collagen I was constantly
high, and the expression of a-SMA was increased. The
differences were even higher when TGF-b was present
[10].
In the tissue, fibrocytes can also play a role in angio-
genesis. For example, in vitro, fibrocytes produce a num-
ber of pro-angiogenic factors such as basic fibroblast
growth factor (bFGF), vascular endothelial growth factor
(VEGF), granulocyte-macrophage colony-stimulating
factor (GM-CSF), interleukin (IL)-1, IL-8, and macro-
phage colony-stimulating factor (M-CSF). These factors
induce migration, proliferation, and alignment of
endothelial cells into tube-like structures [11]. Fibrocytes
express matrix metalloproteinases (MMP)-2, MMP-7,
MMP-8, and MMP-9, which can degrade ECM mole-
cules. Such proteinases can also alter the behavior of
intra- and extracellular proteins and further regulate the
fibrocytes’ possibility for proliferation, adhesion, migra-
tion, and chemotaxis [12].
Fibrocytes have to be recruited from the bone marrow
to the injured tissue, and one of the possibilities for
recruitment is the CXCR4-stromal cell-derived factor
(SDF)-1/CXCL12 axis. SDF-1/CXCL12 belongs to the
CXC family. The only receptor for SDF-1/CXCL12 is
the G-protein-coupled seven-span transmembrane
receptor CXCR4 [13], which is present on its target cell,
e.g., the fibrocyte. Binding to receptor causes several
changes to the fibrocyte: increased secretion of MMPs,
VEGF, and nitric oxide (NO), as well as cytoskeletal
rearrangements which give increased mobility and che-
motaxis [14]. The surrounding ECM forms a micro-
environment to which cells can attach, and the ECM
forms the basement membrane located under the
epithelial and endothelial cells. The main components of
the ECM are collagens, proteoglycans, hyaluronan, and
other glycoproteins. The ECM functions as a reservoir
for growth factors and chemokines, and it is also a
water-absorbent gel mass that gives the tissue its specific
features. Under physiological conditions, the ECM turn-
over rate is highly controlled. Under pathological condi-
tions, such as during tissue repair, there is a higher rate
of synthesis and/or lower rate of degradation. The
remodelling is closely associated with inflammatory pro-
cesses, and some molecules involved in inflammation,
such as hyaluronan, fibronectin, and fibrinogen, appear
to increase the fibrocyte’s sensitivity to SDF-1/CXCL12
[14,15] (Figure 1).
The importance of the CXCR4 - SDF-1/CXCL12 axis
has been shown by Phillips et al.u s i n gab l e o m y c i n
model of lung fibrosis. Mice treated with anti-CXCL12
antibodies had significantly lower levels of collagen and
a-SMA than mice treated with control antibodies [16].
Another possible mechanism for recruitment is a gradi-
ent of the chemokine secondary lymphoid tissue chemo-
kine/chemokine ligand 21 (SLC/CCL21) [17]. It is
Figure 1 Dynamic/temporal local micro-environmental niche. The CXCR4-expressing fibrocytes are recruited from the circulation to the
tissue by a gradient of stromal cell-derived factor (SDF)-1/CXCL12. In the tissue the fibrocytes move and interact with the dynamic/temporal
local micro-environmental niche consisting of a broad array of extracellular matrix (ECM) molecules such as collagens, proteoglycans, hyaluronan,
and glycoproteins. The ECM forms a network and acts as a supporting structure for tissue integrity. It is very essential that the ECM can also
function as a reservoir for a large number of growth factors and cytokines, e.g., SDF-1/CXCL12, transforming growth factor (TGF)-b, interleukin
(IL)-8, tumor necrosis factor (TNF)-a, platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF), just to mention some
examples (generalized as violet spots in the figure) [55,56]. However, in disease states, the structure and composition of the ECM is changed, and
that strongly affects the activity of cells in the niche. The alteration of the ECM, of course, is dependent on type of disease, state of disease,
gene signature, age, gender, nutrition, infection, and also physical location in the pulmonary tree. It is important that the expression of the
haematopoietic surface receptors, CD34, CD45, and CXCR4, on the fibrocytes gradually decreases, whereas the expression of the mesenchymal
markers, such as collagen, fibronectin, and proteoglycans, gradually increases during the fibrocytes’ journey through the tissue. The fibrocyte can
also migrate to the lumen of the airway, and it has been detected there in both asthma and IPF.
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in lung tissue under inflammatory conditions. The
receptor for SLC/CCL21 is CCR7, but it is only
expressed by less than 10% of circulating fibrocytes [9].
This way of recruitment has been studied mostly in
papers on renal fibrosis [5,18].
When fibrocytes have entered an injured tissue, they
migrate through the tissue and are attracted to specific
cytokines that are bound to the ECM. In disease-specific
matrix (described below), the cytokine composition
influences recruitment, differentiation and behaviour of
fibrocytes, e.g., SDF-1 induces migration by interacting
with CXCR4. The markers on the fibrocytes change dur-
ing recruitment in the injured tissue. The expression of
mesenchymal markers increases, while haematopoietic
markers decrease [17] (Figure 1). In many ways fibro-
cytes differ from fibroblasts. An immunologically impor-
tant difference is antigen presentation. Fibrocytes
express both MHC class I and class II antigens and co-
factors CD80 and CD86. Furthermore, fibrocytes can
migrate to lymphatic organs and sensitise naive T-cells.
Previously, this feature was only thought to be a task of
dendritic cells [19].
Another possible goal for the differentiation of fibro-
c y t e si st ob e c o m ea d i p o c y t e sa n dc h o n d r o c y t e s .T h e
differentiation to adipocytes is driven by specific adipo-
genetic hormones and cytokines which follow activation
of specific adipocyte genes. On the other hand, TGF-b
inhibits this differentiation by activating stress-activated
protein kinase/c-Jun NH2-terminal kinase mitogen acti-
vated protein kinase (SAPK/JNK MAPK), which is nor-
mally suppressed during differentiation to adipocytes
[20]. Furthermore, the differentiation to chondrocytes is
driven by TGF-b3 together with a medium that differ-
entiates mesenchymal stem cells to chondrocytes [21].
Interestingly, fibrocytes that have a chondrocyte-like
phenotype show an increased expression of aggrecan
and collagen [21].
Tissue repair in lung disorders
Today, both fibrocytes and fibroblasts are known to be
important in wound healing as ECM-producing cells
that function in response to injury. We also know that
they can release cytokines and growth factors that are
central for remodelling. In the lung, fibrosis can occur
at different locations – at the macro-level in the central
part of the lung, at the micro-level in the distal alveolar
parenchyma, and something in-between, in the small
airways. In this review we have included three different
patient groups, believed to differ somewhat in the pri-
mary site of fibrotic deposition. In asthma, the basement
membrane, which is located below the epithelial layer, is
thickened because of accumulation of collagens and pro-
teoglycans [22] (Figure 2a). In idiopathic pulmonary
fibrosis (IPF), fibroblastic foci occur in demarcated
areas, which are rich in ECM and proteoglycans, but
with few cells [23] (Figure 2b). In obliterative bronchio-
litis (OB), the small airways are obliterated with ECM
[24-26], where the proteoglycans function as “staples” to
attach the connective tissue. In OB, the parenchymal
part of the lung is also involved with thickening of the
alveolar septa [27] (Figure 2c).
The above mentioned disorders are chronic diseases
that involve remodelling of both the airways and the
pulmonary vessels. The remodelling processes have
many differences, but, surprisingly, also many similari-
ties even though the underlying pathophysiological
mechanisms are different. Remodelling usually starts
with an epithelial injury that later gives rise to structural
changes in the airways and in the lung. The origins of
these disorders are different, but they have a common
denominator – the ECM deposition changes the lung
a b c c
Figure 2 Characteristic tissue niche in chronic airway diseases. Panel (a) shows a histological section from a patient with IPF, characterized
by a fibroblastic foci (outlined area) located below the epithelial layer (arrows). The fibroblastic foci is an area rich in ECM but with only few
cells with a stretched morphology, located in parallel to the alveolar septa cells. Panel (b) shows a histological section from a patient with
asthma, characterized by thickening of the basement membrane (arrows), shedding of the epithelial layer (closed arrowheads) and formation of
peribronchial fibrosis (open arrowheads). Panel (c) shows a partially obliterated bronchiole (outlined area) in a patient with OB after lung
transplantation. OB is histologically identified as ECM plugs with few fibroblasts. Original magnification 20×. Scale bar = 100 μm.
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decreased lung function.
Niche plasticity
Idiopathic Pulmonary Fibrosis
Many cell types are important in the pathology of IPF,
but fibroblasts with their ability to produce matrix mole-
cules are of special interest. Studies have shown that
both the synthesis and the degradation of the ECM give
rise to an ECM composition that is characteristic for
fibrotic disease. In IPF, the tissue niche in the lungs
contains approximately two to three times more ECM
than healthy lung tissue, and the IPF fibrosis consists
primarily of fibril-forming collagens (I, III, V, VI and
VII), fibronectin, elastin, and proteoglycans [28] (Figure
1). Both proteases and inhibitors of those play an essen-
tial role in the degradation of the ECM. In tissues from
patients with IPF, fibroblastic foci have been identified
as discrete areas rich in ECM but with few cells. The
cells in the fibroblast foci are arranged in an out-
stretched and parallel arrangement relative to the other
cells and parallel to the alveolar septa [29] (Figure 2a). It
h a sb e e ns p e c u l a t e dt h a tf i b r o b l a s tf o c i ;p l a yak e yr o l e
in the destruction of the normal lung structure, are a
negative prognostic factor and lead to the progressive
and irreversible disorder [29]. Interestingly, the number
of circulating fibrocytes is increased in patients with
IPF, and the level is further elevated in patients during
an acute exacerbation [30].
A possible origin of the fibroblasts in IPF is recruit-
ment of fibrocytes from the bone marrow. The expres-
sion of CXCR4, and its ligand SDF-1/CXCL12, is known
to be up-regulated under hypoxic conditions by
hypoxia-induced factor 1a (HIF-1a) [31,32]. The bone
marrow is hypoxic as compared to the surrounding ves-
sels, and the bone marrow expresses SDF-1/CXCL12.
An injury in the lung leads to increased levels of SDF-1/
CXCL12 in the plasma in bronchoalveolar lavage fluid
(BALF) [33], and fibrocytes are released from the bone
marrow enabling them to migrate over a chemotactic
gradient to the injured lung, where SDF-1/CXCL12 is
expressed [34]. The fibrocytes express MMPs, which
facilitate their transendothelial and tissue migration.
Furthermore, the MMPs also act as a potential partici-
pant in the remodelling of the ECM [12].
The numbers of fibrocytes can be correlated to the
structural changes in all three diseases. In IPF, the
amounts of fibroblast/myofibroblast foci are a negative
prognostic factor, the more foci, the worse the prognosis
[35]. After normal wound healing, the fibroblasts and
myofibroblasts should be reduced by apoptosis, but in
IPF, and especially in fibroblast foci, the numbers of
fibroblasts and myofibroblasts remain constant [36]. It
has been speculated that fibroblastic foci, with their
specific milieu, have a composition of cytokines, growth
factors, and tissue inhibitor of metalloproteinases
(TIMP) that cause fibroblasts and myofibroblasts to
become apoptosis-resistant. Therefore, the ECM is pro-
duced in excess. However, the fibrocytes identified in
t h el u n gt i s s u eo fp a t i e n t sw i t hI P Fa r en o tl o c a t e d
inside the foci, but are located in close proximity to the
foci in areas with ongoing signs of inflammation [33]
Those adjacent areas would later become fibroblastic
foci. One could speculate that fibrocytes that have been
recruited towards the fibroblast foci already have been
differentiated into fibroblasts or myofibroblasts during
the migration.
Asthma
The remodelling and accumulation of ECM are also his-
tological features of asthma, where many cell types with
different features are involved. The structural cells
involved in asthma include epithelial cells, smooth mus-
cle cells, and (myo)fibroblasts. The fibrosis, and for
asthma characteristic tissue niche, is subepithelial. There
is a thickening of the lamina reticularis which contains
collagens I, III, IV, VI, tenascin, and fibronectin [37-40].
This location is also abundant in fibroblasts and myofi-
broblasts in the asthma patient, while the proteoglycans,
versican, biglycan, and decorin, accumulate in the sub-
mucosa below the epithelium in bronchial biopsies from
asthma patients [38] (Figure 2b).
Nihlberg et al. have shown that there is both a central
and a distal shift of the ECM composition, such as
increased levels of versican and collagen, which the
fibrocytes have to pass when they are recruited from the
blood to the injured part of the lung. [22]. There, in the
injured area, cytokines such as TGF-b, which are bound
to the ECM, transform the fibrocytes to matrix-produ-
cing (myo)fibroblasts. Patients with chronic persistent
obstructive asthma have higher levels of TGF-b and
increased numbers of circulating fibrocytes than patients
with asthma who have no loss of lung function [41].
A common technique to study fibrocytes in vitro is to
cultivate them on fibronectin coated dishes, which
allows the fibrocytes to attach to make further detailed
analysis on biological activity and behaviour of these
cells. Those type of studies have been performed of cir-
culating fibrocytes from asthmatic patients, IPF patients,
and healthy controls [9,20,42]. However, there are many
questions to be solved concerning fibronectins’ possibi-
lity to affect fibrocytes and the role of fibronectins in
the tissue niche in these diseases [43].
Nihlberg et al. identified fibrocytes beneath the lamina
reticularis in bronchial biopsies from patients with mild
asthma, and the number of fibrocytes was correlated
with the thickness of the basement membrane. The
asthmatic patients were divided as to whether fibroblast-
like cells could, or could not, be established from BALF.
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showed both more fibrocytes in the tissue and increased
numbers of eosinophils in BALF. It is possible that this
is a result of on ongoing inflammation that contributes
to fibrocyte recruitment [44].
Obliterative bronchiolitis
Obliterative bronchiolitis (OB) is a common conse-
quence of both lung transplantation and bone marrow
transplantation (affecting 60% and 6%, respectively)
[45,46]. The tissue process starts with lymphocyte infil-
tration in the submucosa and injury of the mucosa and
epithelial cell layer, and that results in recruitment of
ECM-producing fibroblasts or their progenitor cells,
such as fibrocytes. Histologically, the rejection is seen as
an ECM plug with few fibroblasts in the bronchioles
[24-26] (Figure 2c). The growth factors involved in the
fibro-proliferative phase of the chronic rejection are pla-
t e l e t - d e r i v e dg r o w t hf a c t o r( P D G F )[ 4 7 ]a n dT G F - b
[48], which are known to up-regulate ECM deposition.
We found that at six months after lung transplanta-
tion the lung-tissue niche was changed. Versican and
decorin production by fibroblasts was increased. After
TGF-b stimulation, the fibroblasts produced even higher
levels of versican and biglycan in patients that went on
to develop OB as compared with patients without any
signs of rejections [49].
There is a thickening of the alveolar parenchyma in
patients with OB after lung or bone marrow transplan-
tation. Furthermore, there is a correlation between the
thickening and the greater number of fibrocytes in the
tissue. Thickening of the parenchyma could give
reduced lung function which is a criterion for OB. The
vessels in OB patients are also remodelled in terms of
increased amounts of endothelial layer and size of the
lumen. There is a correlation between the remodelled
vessels and the greater number of fibrocytes in the tis-
sue [27].
The common denominators of the remodelling are
fibrocytes – and, more speculatively, local hypoxia
The interactions between HIF-1a and HIF-1b,S D F - 1
and CXCR4, VEGF and VEGFR during angiogenesis and
hypoxia are known to be important in many diseases,
including fibrotic disorders. The two subunits, HIF-1a
and HIF-1b, together form a transcription factor that
regulates expression of about 100 genes that are impor-
tant in mechanisms such as anaerobic metabolism,
angiogenesis, and apoptosis [50]. Under normal oxygen
levels, HIF-1a is degraded and the complex with HIF-1b
does not occur. Hypoxia increases the expression of
SDF-1 in endothelial cells, epithelial cells, and in cells
that are in stress after an injury. Furthermore, expres-
sion of its receptor, CXCR4 [51], is also elevated. A
number of cells are known to express CXCR4 on their
surfaces: fibrocytes, lymphocytes, muscle cells, and
endothelial progenitor cells. Likewise, the expression of
VEGF and its receptor, VEGFR, is also up-regulated to
promote angiogenesis. The remodelled vessels, with
enlarged lumen and greater endothelial cell area, that
are identified in patients with OB after lung or bone
marrow transplantation could in fact be a result of local
hypoxia. Furthermore, an enlarged vessel gives a larger
entrance area for the fibrocyte. The number of cells that
co-express prolyl 4-hydroxylase and VEGFR2 is higher
in patients with OB than in control individuals, and
further, there is a correlation with the number of fibro-
cytes identified in the tissue (unpublished data). In
asthma and IPF, vessel remodelling has also been stu-
died, and in both diseases angiogenesis is involved that
could be driven by hypoxic forces. In asthma, the vessels
located in the bronchia and in the small airways are
increased in number. In IPF the angiogenesis is depen-
dent on an imbalance between IL-8 which is angiogenic,
and IFN-g, which is angiostatic [52-54].
Fibrocytes in the lumen of the airway
After the fibrocytes have entered the tissue, the fibro-
cytes can differentiate into other cell types and/or con-
tinue to migrate to the lumen of the airway. Asthmatic
patients and IPF patients differ regarding the types of
cells found in the BALF. In asthmatic patients, a rela-
tively high proportion of the fibroblast population
expresses fibrocyte markers such as CD34, CD45RO,
and a-SMA [44]. In the IPF patients, 1.0-3.4% of the
cells were of mesenchymal origin. It is possible that this
cell population is of fibrocytic origin but has differen-
tiated because of the local environment in the IPF lung,
and for this reason does not express CXCR4 (Figure 1).
We are still missing data about fibrocytes in BALF from
patients with OB. The pathophysiological obliteration of
the small airways probably makes it difficult for fibro-
cytes to migrate to the lumen, at least in the occluded
part of the lung.
Conclusions
Each of the three diseases, asthma, IPF and OB, has its
own specific local niche that influences the fibrocyte
phenotype. In IPF, there is a correlation between the
number of fibrocytes in the tissue and the number of
fibroblastic foci. In asthma, thicker basement mem-
branes are accompanied by fibrocytes in the BALF. In
OB, there is a correlation between the number of fibro-
cytes and both vessel remodelling and thickening of the
alveolar parenchyma. The fibrocytes can differentiate
into fibroblasts which produce ECM molecules which
further create or preserve each disorder’ss p e c i f i cn i c h e .
Even thought we still do not know to what degree the
fibrocytes contribute to each disease, it might be of
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Page 5 of 7interest to inhibit recruitment and differentiation of
fibrocytes because they are associated with pathological
airway remodelling.
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